Granules India gets licence from DRDO to manufacture, market COVID-19 drug

03 Sep 2021 Evaluate

Granules India has received a license from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG). Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as an adjunct therapy in moderate to severe COVID-19 patients.

The company is working closely with the DRDO team to launch the product in India at the earliest. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

616.75 9.00 (1.48%)
07-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1854.15
Dr. Reddys Lab 1350.75
Cipla 1497.80
Lupin 2357.65
Zydus Lifesciences 1001.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.